Online inquiry

IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6276MR)

This product GTTS-WQ6276MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC), T cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6276MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10069MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ988MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ5756MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ8278MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ12095MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ3318MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ5938MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ1457MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW